Advanced

A FISH-based method for assessment of HER-2 amplification status in breast cancer circulating tumor cells following CellSearch isolation

Frithiof, Henrik LU ; Aaltonen, Kristina LU and Rydén, Lisa LU (2016) In OncoTargets and Therapy 2016(9). p.7095-7103
Abstract
Amplification of the HER-2/neu (HER-2) proto-oncogene occurs in 10%–15% of primary breast cancer, leading to an activated HER-2 receptor, augmenting growth of cancer cells. Tumor classification is determined in primary tumor tissue and metastatic biopsies. However, malignant cells tend to alter their phenotype during disease progression. Circulating tumor cell (CTC) analysis may serve as an alternative to repeated biopsies. The Food and Drug Administration-approved CellSearch system allows determination of the HER-2 protein, but not of the HER-2 gene. The aim of this study was to optimize a fluorescence in situ hybridization (FISH)-based method to quantitatively determine HER-2 amplification in breast cancer CTCs following CellSearch-based... (More)
Amplification of the HER-2/neu (HER-2) proto-oncogene occurs in 10%–15% of primary breast cancer, leading to an activated HER-2 receptor, augmenting growth of cancer cells. Tumor classification is determined in primary tumor tissue and metastatic biopsies. However, malignant cells tend to alter their phenotype during disease progression. Circulating tumor cell (CTC) analysis may serve as an alternative to repeated biopsies. The Food and Drug Administration-approved CellSearch system allows determination of the HER-2 protein, but not of the HER-2 gene. The aim of this study was to optimize a fluorescence in situ hybridization (FISH)-based method to quantitatively determine HER-2 amplification in breast cancer CTCs following CellSearch-based isolation and verify the method in patient samples. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
OncoTargets and Therapy
volume
2016
issue
9
pages
7095 - 7103
publisher
Dove Medical Press Ltd.
external identifiers
  • scopus:84996957449
  • wos:000387902600001
ISSN
1178-6930
DOI
10.2147/OTT.S118502
language
English
LU publication?
yes
id
52e3c853-08dc-46cb-b838-0a687803bbfb
date added to LUP
2016-11-29 11:27:39
date last changed
2017-09-03 05:15:37
@article{52e3c853-08dc-46cb-b838-0a687803bbfb,
  abstract     = {Amplification of the HER-2/neu (HER-2) proto-oncogene occurs in 10%–15% of primary breast cancer, leading to an activated HER-2 receptor, augmenting growth of cancer cells. Tumor classification is determined in primary tumor tissue and metastatic biopsies. However, malignant cells tend to alter their phenotype during disease progression. Circulating tumor cell (CTC) analysis may serve as an alternative to repeated biopsies. The Food and Drug Administration-approved CellSearch system allows determination of the HER-2 protein, but not of the HER-2 gene. The aim of this study was to optimize a fluorescence in situ hybridization (FISH)-based method to quantitatively determine HER-2 amplification in breast cancer CTCs following CellSearch-based isolation and verify the method in patient samples.},
  author       = {Frithiof, Henrik and Aaltonen, Kristina and Rydén, Lisa},
  issn         = {1178-6930},
  language     = {eng},
  number       = {9},
  pages        = {7095--7103},
  publisher    = {Dove Medical Press Ltd.},
  series       = {OncoTargets and Therapy},
  title        = {A FISH-based method for assessment of HER-2 amplification status in breast cancer circulating tumor cells following CellSearch isolation},
  url          = {http://dx.doi.org/10.2147/OTT.S118502},
  volume       = {2016},
  year         = {2016},
}